
Nadezhda Duffy, Centers for Disease Control and Prevention
Cedric J. Brown, Centers for Disease Control and Prevention
Sandra N. Bulens, Centers for Disease Control and Prevention
Wendy Bamberg, Colorado Department of Public Health and Environment
Sarah J. Janelle, Colorado Department of Public Health and Environment
Jesse Jacob, Emory University
Chris Bower, Georgia Emerging Infections Program
Lucy Wilson, Maryland Department of Health and Mental Hygiene
Elisabeth Vaeth, Maryland Department of Health and Mental Hygiene
Ruth Lynfield, Minnesota Department of Health

Only first 10 authors above; see publication for full author list.

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: Oxford University Press (OUP) | 2017-10-04, Pages S50-S50
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofx162.118
Permanent URL: https://pid.emory.edu/ark:/25593/s6g7m

Final published version: http://dx.doi.org/10.1093/ofid/ofx162.118

Copyright information:
© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed December 14, 2017 11:24 AM EST
CCN-SIRs, their relative position in the quartile distributions of SIR_NEW and SIR_OLD remained the same. The discrepancies between SIR_NEW and SIR_OLD tended to be larger among CCNs with high SIRs.

**Conclusion.**  The updated national pooled mean SIRs were close to 1.0, validating the potential use of new risk adjustment models and baseline as updated benchmarks for tracking CDI and MRSA prevention progress. The shifts in CCN-level SIRs between old and new baselines were not large, indicating a modest impact of new baselines for tracking CDI and MRSA prevention progress. The shifts in CCN-level SIRs ing the potential use of new risk adjustment models and baseline as updated benchmarks for tracking CDI and MRSA prevention progress. 

**Disclosures.**  All authors: No reported disclosures.


Ndezahla Dufy, MD, MPH1; Cedric J. Brown, MS1; Sandra N. Bulens, MPH1; Wendy Bamberg, MD2; Sarah J. Janelle, MPH, CIC1; Jesse T. Jacob, MD3; Chris Bower, MPH4; Lucy Wilson, MD5; Elisabeth Vaeth, MPH6; Ruth Lynfield, MD, FIDSA7; Paula Snippes Vagnone, MT (ASCP)8; Erinn C. Phipps, DVM, MPH9; Emily S. Hancock, MS3; Ginweta Dumiati, MD, FSHEA10; Cathleen Conancock, MPH11; Zintars G. Beldavs, MS12; P. Maureen Cassidy, MPH13; Marion Kainer, MBBS, MPH, FSHEA14; Daniel Mulleta, MD, MPH15; Isaac See, MD1; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia; Colorado Department of Public Health and Environment, Denver, Colorado; Georgia Emerging Infections Program, Decatur, Georgia; Emory University School of Medicine, Atlanta, Georgia; Atlanta Veterans Affairs Medical Center, Decatur, Georgia; Maryland Department of Health and Mental Hygiene, Baltimore, Maryland; Minnesota Department of Health, St. Paul, MN; University of New Mexico, New Mexico Emerging Infections Program, Albuquerque, New Mexico; New Mexico Emerging Infections Program, University of New Mexico, Albuquerque, New Mexico; Center for Community Health, University of Rochester Medical Center, Rochester, New York; NY Emerging Infections Program, Center for Community Health, University of Rochester Medical Center, Rochester, New York; Oregon Health Authority, Portland, Oregon; Tennessee Department of Health, Nashville, Tennessee

**Session:** 215. National Trends in HAIs

**Saturday, October 7, 2017: 8:30 AM**

**Background.**  Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent threat in the United States because of high morbidity and mortality; few treatment options, and potential for rapid spread among patients. To assess for changes in CRE epidemiology and risk among populations, we analyzed CDC Emerging Infections Program (EIP) 2012–2015 surveillance data for CRE.

**Methods.**  Active, population-based CRE surveillance was initiated in January 2012 at 3 EIP sites (GA, MN, OR) and expanded to 5 additional sites (CO, MD, NM, NY, TN) by 2014. An incident case was the first Escherichia coli, Enterobacter, or Klebsiella isolate (non-susceptible to at least one carbapenem and resistant to at least third-generation cephalosporins tested) collected from urine or a normally sterile body site from a patient during a 30-day period. Data were collected from patients’ medical records. Cases were hospital-onset (HO) or long-term care facility (LTFCF) onset if patients were in the respective facility ≥3 days prior to culture or at the time of culture; and community-onset (CO) otherwise. We calculated incidence rates based on census data for EIP sites and described by type of infection onset.

**Results.**  A total of 1,582 incident CRE cases were reported in 2012–2015. Most cases (88%) were identified through urine cultures; 946 (60%) were female, and median age was 66 years (interquartile range: 55–77). The median incidence by site was 2.95 per 100,000 population (range: 0.35–8.98). Among the three sites with four full years of data, a different trend was seen in each (Figure). Trends in GA and MN were statistically significant, and no significant trend was seen in OR. Overall, 480 cases (30%) were HO, 524 (33%) were LTFCF onset, and 578 (37%) were CO. Of CO cases, 308 (53%) had been hospitalized, admitted to a long-term acute care hospital or were a LTCF resident in the prior year.

**Conclusion.**  CRE incidence varied more than 20-fold across surveillance sites, with evidence of continued increases in MN. Measuring impact of programs aimed at reducing CRE transmission in other regions will require obtaining local data to identify cases occurring during and after healthcare facility discharge. Further study of changes in incidence in some settings and areas might offer opportunities to refine and expand effective control strategies.

**Disclosures.**  All authors: No reported disclosures.

1771. The Effect of National Healthcare Safety Network (NHSN) Rebaselining on Community Hospital SIRs

Christopher Hostler, MD, MPH1,2; Rebekah W. Moehring, MD, MPH1,2; Arthur W. Baker, MD, MPH3; Becky Smith, MD4; Linda Adcock, RN, BSN, CIC4; Brittain Wood, RN, BSN, CIC5; Evelyn Cook, RN, CIC6; Linda Cribbs, BSMT, CIC6; Andrea Cromer, RN, CIC7; Kathy Lockamy, RN, CIC7; Susan Louis, RN, CIC7; Polly Padgett, RN, BSN, CIC7; Christopher W Woods, MD, MPH, FIDSA8,9; Daniel Sexton, MD10; Deverick Anderson, MD, MPH, FSHEA, FIDSA11,12; and Sarah S. Lewis, MD MPH1,2; Duke Center for Antimicrobial Stewardship and Infection

Disclosures.  All authors: No reported disclosures.